Pharmacokinetics and placental transfer of single-dose tenofovir 1% vaginal gel in term pregnancy

Richard Beigi, Lisa Noguchi, Teresa Parsons, Ingrid Macio, Ratiya P. Kunjara Na Ayudhya, Jianmeng Chen, Craig Hendrix, Benoît Mâsse, Megan Valentine, Jeanna Piper, D. Heather Watts

Research output: Contribution to journalArticle

Abstract

Tenofovir (TFV) 1% vaginal gel has been found to decrease sexual transmission of human immunodeficiency virus. To initiate investigations during pregnancy, 16 healthy pregnant women scheduled for cesarean delivery received a single application of TFV gel preoperatively. Maternal serum drug concentrations were determined and fetal cord blood, amniotic fluid, placental tissue, and endometrial tissue specimens were collected. The median maternal peak concentration and cord blood TFV concentrations were 4.3 and 1.9 ng/mL, respectively (∼100-and 40-fold lower than after TFV oral dosing, respectively). No adverse events were related to the use of TFV gel. These findings support ongoing and future investigations of TFV gel in pregnancy.

Original languageEnglish (US)
Pages (from-to)1527-1531
Number of pages5
JournalJournal of Infectious Diseases
Volume204
Issue number10
DOIs
StatePublished - Nov 15 2011

Fingerprint

Tenofovir
Foams and Jellies Vaginal Creams
Pharmacokinetics
Pregnancy
Fetal Blood
Gels
Mothers
Amniotic Fluid
Pregnant Women
HIV

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy

Cite this

Beigi, R., Noguchi, L., Parsons, T., Macio, I., Kunjara Na Ayudhya, R. P., Chen, J., ... Watts, D. H. (2011). Pharmacokinetics and placental transfer of single-dose tenofovir 1% vaginal gel in term pregnancy. Journal of Infectious Diseases, 204(10), 1527-1531. https://doi.org/10.1093/infdis/jir562

Pharmacokinetics and placental transfer of single-dose tenofovir 1% vaginal gel in term pregnancy. / Beigi, Richard; Noguchi, Lisa; Parsons, Teresa; Macio, Ingrid; Kunjara Na Ayudhya, Ratiya P.; Chen, Jianmeng; Hendrix, Craig; Mâsse, Benoît; Valentine, Megan; Piper, Jeanna; Watts, D. Heather.

In: Journal of Infectious Diseases, Vol. 204, No. 10, 15.11.2011, p. 1527-1531.

Research output: Contribution to journalArticle

Beigi, R, Noguchi, L, Parsons, T, Macio, I, Kunjara Na Ayudhya, RP, Chen, J, Hendrix, C, Mâsse, B, Valentine, M, Piper, J & Watts, DH 2011, 'Pharmacokinetics and placental transfer of single-dose tenofovir 1% vaginal gel in term pregnancy', Journal of Infectious Diseases, vol. 204, no. 10, pp. 1527-1531. https://doi.org/10.1093/infdis/jir562
Beigi R, Noguchi L, Parsons T, Macio I, Kunjara Na Ayudhya RP, Chen J et al. Pharmacokinetics and placental transfer of single-dose tenofovir 1% vaginal gel in term pregnancy. Journal of Infectious Diseases. 2011 Nov 15;204(10):1527-1531. https://doi.org/10.1093/infdis/jir562
Beigi, Richard ; Noguchi, Lisa ; Parsons, Teresa ; Macio, Ingrid ; Kunjara Na Ayudhya, Ratiya P. ; Chen, Jianmeng ; Hendrix, Craig ; Mâsse, Benoît ; Valentine, Megan ; Piper, Jeanna ; Watts, D. Heather. / Pharmacokinetics and placental transfer of single-dose tenofovir 1% vaginal gel in term pregnancy. In: Journal of Infectious Diseases. 2011 ; Vol. 204, No. 10. pp. 1527-1531.
@article{334902df79284634998b658e0f16c360,
title = "Pharmacokinetics and placental transfer of single-dose tenofovir 1{\%} vaginal gel in term pregnancy",
abstract = "Tenofovir (TFV) 1{\%} vaginal gel has been found to decrease sexual transmission of human immunodeficiency virus. To initiate investigations during pregnancy, 16 healthy pregnant women scheduled for cesarean delivery received a single application of TFV gel preoperatively. Maternal serum drug concentrations were determined and fetal cord blood, amniotic fluid, placental tissue, and endometrial tissue specimens were collected. The median maternal peak concentration and cord blood TFV concentrations were 4.3 and 1.9 ng/mL, respectively (∼100-and 40-fold lower than after TFV oral dosing, respectively). No adverse events were related to the use of TFV gel. These findings support ongoing and future investigations of TFV gel in pregnancy.",
author = "Richard Beigi and Lisa Noguchi and Teresa Parsons and Ingrid Macio and {Kunjara Na Ayudhya}, {Ratiya P.} and Jianmeng Chen and Craig Hendrix and Beno{\^i}t M{\^a}sse and Megan Valentine and Jeanna Piper and Watts, {D. Heather}",
year = "2011",
month = "11",
day = "15",
doi = "10.1093/infdis/jir562",
language = "English (US)",
volume = "204",
pages = "1527--1531",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Pharmacokinetics and placental transfer of single-dose tenofovir 1% vaginal gel in term pregnancy

AU - Beigi, Richard

AU - Noguchi, Lisa

AU - Parsons, Teresa

AU - Macio, Ingrid

AU - Kunjara Na Ayudhya, Ratiya P.

AU - Chen, Jianmeng

AU - Hendrix, Craig

AU - Mâsse, Benoît

AU - Valentine, Megan

AU - Piper, Jeanna

AU - Watts, D. Heather

PY - 2011/11/15

Y1 - 2011/11/15

N2 - Tenofovir (TFV) 1% vaginal gel has been found to decrease sexual transmission of human immunodeficiency virus. To initiate investigations during pregnancy, 16 healthy pregnant women scheduled for cesarean delivery received a single application of TFV gel preoperatively. Maternal serum drug concentrations were determined and fetal cord blood, amniotic fluid, placental tissue, and endometrial tissue specimens were collected. The median maternal peak concentration and cord blood TFV concentrations were 4.3 and 1.9 ng/mL, respectively (∼100-and 40-fold lower than after TFV oral dosing, respectively). No adverse events were related to the use of TFV gel. These findings support ongoing and future investigations of TFV gel in pregnancy.

AB - Tenofovir (TFV) 1% vaginal gel has been found to decrease sexual transmission of human immunodeficiency virus. To initiate investigations during pregnancy, 16 healthy pregnant women scheduled for cesarean delivery received a single application of TFV gel preoperatively. Maternal serum drug concentrations were determined and fetal cord blood, amniotic fluid, placental tissue, and endometrial tissue specimens were collected. The median maternal peak concentration and cord blood TFV concentrations were 4.3 and 1.9 ng/mL, respectively (∼100-and 40-fold lower than after TFV oral dosing, respectively). No adverse events were related to the use of TFV gel. These findings support ongoing and future investigations of TFV gel in pregnancy.

UR - http://www.scopus.com/inward/record.url?scp=80054773666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054773666&partnerID=8YFLogxK

U2 - 10.1093/infdis/jir562

DO - 10.1093/infdis/jir562

M3 - Article

VL - 204

SP - 1527

EP - 1531

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 10

ER -